UBS initiated coverage of Clover Health with a rating of Neutral and set a new price target of $4.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/7/2024 | $4.00 | Neutral | UBS |
| 2/25/2022 | $3.00 → $2.50 | Market Perform | SVB Leerink |
| 2/2/2022 | $7.00 → $3.00 | Underperform → Market Perform | Cowen & Co. |
| 2/2/2022 | $6.00 | Buy | Canaccord Genuity |
| 1/19/2022 | $3.00 | Market Perform | SVB Leerink |
| 1/10/2022 | $9.00 → $3.50 | Neutral | Citigroup |
| 1/7/2022 | $9.00 → $3.50 | Neutral → Underperform | Credit Suisse |
| 11/15/2021 | $8.00 → $9.00 | Neutral | Credit Suisse |
FRANKLIN, Tenn., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), today announced that it will report third quarter 2024 financial results after market close on Wednesday, November 6, 2024. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on November 6, 2024, to discuss Clover Health's third quarter 2024 business and financial results. Third Quarter 2024 Conference Call and Webcast Details: What: Clover Health's Third Quarter 2024 Earnings Conference CallWhen: Wednesday, November 6, 2024, at 5:00 p.m. Eastern TimeDial In: To access the call via telephone please dial 800-579-2543 (for U.S. callers) or 785-424-1
Total Revenue growth for the Second Quarter of 2024 of 11% year-over-year GAAP Net Income from Continuing Operations during the Second Quarter of 2024 of $7.2 million versus Second Quarter 2023 GAAP loss of $28.9 million Adjusted EBITDA profitability for the Second Quarter of 2024 of $36.2 million versus Second Quarter 2023 Adjusted EBITDA of $9.9 million Increases Full-Year 2024 guidance to Insurance Revenue of $1.35 billion - $1.375 billion and Adjusted EBITDA profitability of $50 million - $65 million FRANKLIN, Tenn., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enab
FRANKLIN, Tenn., July 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced that it will report second quarter 2024 financial results after market close on Monday, August 5, 2024. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on August 5, 2024, to discuss Clover Health's business and financial results. Second Quarter 2024 Conference Call and Webcast Details: What: Clover Health's Second Quarter 2024 Earnings Conference CallWhen: Monday, August 5, 2024, at 5:00 p.m. Eastern TimeDial I
FRANKLIN, Tenn., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced its participation in the following investor conferences: CFO, Peter Kuipers, will present at the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024, at 5:00 p.m. Eastern Time.CFO, Peter Kuipers, will participate in the Canaccord Genuity 2024 Medical Technology, Diagnostics, and Digital Health & Services Forum on Thursday, November 21, 2024.CEO, Andrew Toy, will participate in the Virtual BTIG Digital Health Forum on Monday, November 25, 2024.CFO, Peter Kuipers, will present at the 2024 Citi Global Healthcare Confer
FRANKLIN, Tenn., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), today announced that it will report third quarter 2024 financial results after market close on Wednesday, November 6, 2024. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on November 6, 2024, to discuss Clover Health's third quarter 2024 business and financial results. Third Quarter 2024 Conference Call and Webcast Details: What: Clover Health's Third Quarter 2024 Earnings Conference CallWhen: Wednesday, November 6, 2024, at 5:00 p.m. Eastern TimeDial In: To access the call via telephone please dial 800-579-2543 (for U.S. callers) or 785-424-1
FRANKLIN, Tenn., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Clover Health (NASDAQ:CLOV) ("Clover" or "the Company") has announced the debut of its 2025 Medicare Advantage (MA) plan offerings in New Jersey. Clover offers a range of affordable and flexible healthcare options for Medicare beneficiaries, which are designed to meet the unique needs of New Jersey seniors, especially those on fixed incomes facing rising costs of living. For full plan details, availability, and eligibility visit https://www.cloverhealth.com/plans. "We are proud to reaffirm our commitment to New Jersey by maintaining our affordable benefit-rich PPO plans for 2025," said Jamie Reynoso, Clover's CEO of Medicare Advantage. "
FRANKLIN, Tenn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a leading AI-powered physician enablement platform, today announced the appointment of David Tsay M.D., Ph.D as Chief Medical Officer (CMO). Dr. Tsay will play a key role in advancing Counterpart's clinical strategy and product roadmap for Counterpart Assistant, the company's proprietary AI-powered physician enablement software platform that empowers providers to deliver high-quality, cost-effective care. Counterpart is a subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"). David Tsay is a distinguished physician executive with deep expertise and over two decades of ex
FRANKLIN, Tenn., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health" or "Clover"), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced the appointment of Joseph Brand as Chief Operating Officer (COO) for its Medicare Advantage (MA) plan. Mr. Brand will oversee core MA operations and drive performance improvements, with a focus on improving healthcare delivery in New Jersey by leveraging operational efficiencies and technological innovation. Mr. Brand brings nearly 20 years of healthcare leadership experience, having held prominent positions in healthcare operation
FRANKLIN, Tenn., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced it has appointed Thomas L. Tran to the Company's Board of Directors (the "Board"), and as a member of the Audit Committee. "Tom Tran's appointment to our Board marks a significant enhancement to our strategic financial planning and execution capabilities. With his impressive track record at the helm of finance at public managed care organizations, Tom is uniquely qualified to help guide Clover Health as we advance o
Clover Health Investments's (NYSE:CLOV) short percent of float has fallen 7.26% since its last report. The company recently reported that it has 35.32 million shares sold short, which is 8.81% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.88 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. S
U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 100 points on Monday. Shares of RXO, Inc.. (NYSE:RXO) shares rose sharply in today's pre-market trading after the company inked a definitive agreement to acquire Coyote Logistics from United Parcel Service, Inc. (NYSE:UPS) for $1.025 billion in cash. As per the terms, the transaction disclosed on Sunday will be financed through a combination of equity and debt, including a $300 million equity investment from MFN Partners and a $250 million equity investment from Orbis Investments, both significant shareholders of RXO. RXO shares jumped 13.3% to $22.90 in pre-market trading. Here are some big s
8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)
8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)
8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)
UBS initiated coverage of Clover Health with a rating of Neutral and set a new price target of $4.00
SVB Leerink reiterated coverage of Clover Health Investments with a rating of Market Perform and set a new price target of $2.50 from $3.00 previously
Cowen & Co. upgraded Clover Health Investments from Underperform to Market Perform and set a new price target of $3.00 from $7.00 previously
SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)